Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
27 participants
INTERVENTIONAL
2018-03-13
2019-12-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Patients With Immune Function Abnormalities
NCT00128973
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
NCT07251179
Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19
NCT04800731
Trauma as a Trigger for Autoimmunity
NCT03767712
Obstetrical History and Anti-HLA Antibodies Level
NCT06021925
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Patients with the phenotype (PID and Neutropenia and lymphoproliferation)
FACS analyses
FACS analyses
Target Sequencing by NGS ( Next-generation sequencing)
Target Sequencing by NGS ( Next-generation sequencing)
Whole Exome Sequencing
Whole Exome Sequencing
relatives (parents)
FACS analyses
FACS analyses
Target Sequencing by NGS ( Next-generation sequencing)
Target Sequencing by NGS ( Next-generation sequencing)
Whole Exome Sequencing
Whole Exome Sequencing
Controls
FACS analyses
FACS analyses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FACS analyses
FACS analyses
Target Sequencing by NGS ( Next-generation sequencing)
Target Sequencing by NGS ( Next-generation sequencing)
Whole Exome Sequencing
Whole Exome Sequencing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CVID (Common Variable Immunodeficiency)
* Neutropenia
* Lymphoproliferation
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service d'Immunologie Clinique et VIH - Hôpital Civil
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Guffroy A, Mourot-Cottet R, Gerard L, Gies V, Lagresle C, Pouliet A, Nitschke P, Hanein S, Bienvenu B, Chanet V, Donadieu J, Gardembas M, Karmochkine M, Nove-Josserand R, Martin T, Poindron V, Soulas-Sprauel P, Rieux-Laucat F, Fieschi C, Oksenhendler E, Andre-Schmutz I, Korganow AS; DEFI study group. Neutropenia in Patients with Common Variable Immunodeficiency: a Rare Event Associated with Severe Outcome. J Clin Immunol. 2017 Oct;37(7):715-726. doi: 10.1007/s10875-017-0434-2. Epub 2017 Aug 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6642
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.